Acurx Pharmaceuticals has showcased promising results from its DNA pol IIIC inhibitors at the LED3 Conference, demonstrating advances in antimicrobial treatments.

Acurx Pharmaceuticals reveals groundbreaking findings on DNA pol IIIC inhibitors, showcasing their potential in antibacterial therapy while preserving gut microbiome health.

Acurx provided groundbreaking findings on its DNA pol IIIC inhibitor, ibezapolstat, which shows selective antibacterial properties, at IDWeek 2025.

Acurx Pharmaceuticals showcased significant findings from its research on novel antibiotics at a leading scientific conference, advancing the fight against persistent infections.